Evidence map›Paper›PMID 40537838›Full record

ArticleAlzheimer's research & therapy2025

Kidney function is associated with plasma ATN biomarkers among Hispanics/Latinos: SOL-INCA and HCHS/SOL results.

Natasha Z Anita, Wassim Tarraf, Sayaka Kuwayama, Freddie Márquez, Charles DeCarli, Bharat Thyagarajan, Nora Franceschini, James P Lash, Tanya Johns, Kevin A González and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. APOE and plasma AD biomarkers: The role of genetic ancestry in Hispanics/Latinos.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Natasha Z AnitaDepartment of Neurosciences, University of California, San Diego, 9500 Gilman Dr, La Jolla, San Diego, CA, USA.
Wassim TarrafInstitute of Gerontology & Department of Healthcare Sciences, Wayne State University, Detroit, MI, USA.
Sayaka KuwayamaDepartment of Neurosciences, University of California, San Diego, 9500 Gilman Dr, La Jolla, San Diego, CA, USA.
Freddie MárquezDepartment of Neurosciences, University of California, San Diego, 9500 Gilman Dr, La Jolla, San Diego, CA, USA.
Charles DeCarliDepartment of Neurology, University of California, Davis, Sacramento, CA, USA.
Bharat ThyagarajanDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.
Nora FranceschiniDepartment of Epidemiology, Gillings School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
James P LashDepartment of Medicine, University of Illinois Chicago, Chicago, IL, USA.
Tanya JohnsDepartment of Medicine, Division of Nephrology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, USA.
Kevin A GonzálezDepartment of Neurosciences, University of California, San Diego, 9500 Gilman Dr, La Jolla, San Diego, CA, USA.
Martha DaviglusInstitute for Minority Health Research, College of Medicine, University of Illinois Chicago, Chicago, IL, USA.
Haibo ZhouDepartment of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Ariana M StickelDepartment of Psychology, San Diego State University, San Diego, CA, USA.
Frank J PenedoDepartments of Psychology and Medicine, University of Miami, Coral Gables, USA.
Tatjana RundekDepartment of Neurology and Evelyn F. McKnight Brain Institute, University of Miami, Miami, FL, USA.
Doug GalaskoDepartment of Neurosciences, University of California, San Diego, 9500 Gilman Dr, La Jolla, San Diego, CA, USA.
Hector M GonzálezDepartment of Neurosciences, University of California, San Diego, 9500 Gilman Dr, La Jolla, San Diego, CA, USA. hmg002@health.ucsd.edu.

Funding

UCSD Shiley-Marcos Alzheimer's Disease Research Center P30P30AG062429 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JAMES B BREWER · 2019 to 2026
$34.9M
Study of Latinos-Investigation of Neurocognitive Aging-Alzheimer's diseaseR01AG075758 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Charles DeCarli, Hector M Gonzalez · 2022 to 2026
$21.7M
Pilot Program CoreP30ES027792 · NIEHS · UNIVERSITY OF CHICAGO · PI Gokhan M. Mutlu, Gail S Prins · 2017 to 2026
$13.6M
UCSD Leading the Advancement of Underrepresented Neuroscientists for Change (LAUNCH) Faculty Development ProgramR25NS117367 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Victoria B Risbrough, Joann Trejo · 2020 to 2026
$1.6M
Enhanced Machine Learning Tools for Complex Data Evaluation and Integration in Advancing Health OutcomesR01HL173044 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Baiming Zou, Fei Zou · 2025 to 2026
$1.3M
Diet Related Inflammation and Kidney Function Decline in Racial/Ethnic MinoritiesK23DK124644 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI JOHNS, TANYA · 2021 to 2023
$752k
NHLBI NIH HHS R01 HL173044NIA NIH HHS P30 AG062429NIA NIH HHS R01 AG075758NIA NIH HHS R01AG075758NIDDK NIH HHS K23 DK124644NIEHS NIH HHS P30 ES027792NINDS NIH HHS R25 NS117367
6 · The paper itself

Abstract

backgroundPlasma amyloid-tau-neurodegeneration (ATN) biomarker levels may be influenced by non-brain systems, such as kidney function, which could impact the interpretation of ATN biomarker results, particularly in groups like Hispanic/Latino individuals with higher rates of cardiometabolic health issues. Here, we examine the association between kidney function and plasma ATN markers among a diverse sample of Hispanic/Latino individuals living in the U.S.

methodsData was collected from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL, Visit 1, 2008-2011), the largest prospective cohort study of noninstitutionalized Hispanic/Latino adults in the U.S., and its ancillary study, the Study of Latinos-Investigation of Neurocognitive Aging (SOL-INCA) which was conducted during the second visit of the parent HCHS/SOL study (Visit 2, 2015-2018). SOL-INCA aimed to examine the neurocognitive decline of middle-aged and older Hispanic/Latino adults, and the inclusion criteria were the age of 50-years and older by Visit 2 and completion of battery of neurocognitive tests at Visit 1. Survey linear regression models were used to examine associations between CKD status (estimated glomerular filtration rate [eGFR] < 60 ml/min/1.73m

results5,968 participants were included in the study (mean age 63.4 ± 8.1, 54% women). CKD was associated with higher p-Tau181 (b = 0.82), NfL (b = 11.60) and GFAP levels (b = 31.41), and lower Aβ42/Aβ40 ratio (b=-0.004). Lower eGFR (i.e., reduced kidney function) was associated with higher p-Tau181, NfL, and GFAP levels (b ranges [-0.87 - -0.03]), and lower Aβ42/Aβ40 ratio (b = 0.000). Higher (natural log) uACR was associated with lower Aβ42/Aβ40 ratio and higher levels of all other biomarkers (b ranges [0.24-5.49]). Additionally, CKD, eGFR, and uACR were associated with ATN biomarkers in models adjusted for cardiometabolic risk factors, diabetes and hypertension.

conclusionsCKD status, kidney function and urinary markers of kidney damage are significant confounders in the interpretation of plasma ATN biomarker levels.

Indexed as

Amyloid beta-PeptidesKidneytau ProteinsAgedBiomarkersCohort StudiesFemaleGlial Fibrillary Acidic ProteinGlomerular Filtration RateHispanic or LatinoHumansKidney Function TestsMaleMiddle AgedNeurofilament ProteinsPeptide FragmentsAmyloid beta-PeptidesBiomarkersGlial Fibrillary Acidic Proteinneurofilament protein LNeurofilament ProteinsPeptide Fragmentstau ProteinsAlzheimer's diseaseBiomarkersDementiaKidneyRenal

Identifiers

PMID40537838
PMCPMC12180232

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.